Metgasco Limited (ASX:MEL)

Regulus Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Operating Revenue	2.14	2.37	0.48	-	-	-
Revenue	2.14	2.37	0.48	-	-	-
Revenue Growth (YoY)	23.80%	398.94%	-	-	-	-
Cost of Revenue	1.22	1.23	0.76	-	-	-
Gross Profit	0.93	1.14	-0.29	-	-	-
Selling, General & Admin	0.92	1	1.36	1.53	1.09	1.44
Other Operating Expenses	-	-	0	-	-0.05	-0.05
Operating Expenses	13.66	13.74	1.43	5.91	1.04	1.45
Operating Income	-12.73	-12.6	-1.72	-5.91	-1.04	-1.45
Interest Expense	-1.08	-0.38	-0.05	-0.01	-0	-
Interest & Investment Income	0	0	0	0	0	0.01
Other Non Operating Income (Expenses)	-0.43	-0.22	0.24	-0.2	-0.13	-0.54
EBT Excluding Unusual Items	-14.24	-13.2	-1.53	-6.12	-1.17	-1.98
Gain (Loss) on Sale of Investments	-	-	-	0	-0.01	-5.48
Pretax Income	-14.24	-13.2	-1.53	-6.11	-1.18	-7.46
Net Income	-14.24	-13.2	-1.53	-6.11	-1.18	-7.46
Net Income to Common	-14.24	-13.2	-1.53	-6.11	-1.18	-7.46
Shares Outstanding (Basic)	968	1,089	956	768	524	391
Shares Outstanding (Diluted)	968	1,089	956	768	524	391
Shares Change (YoY)	-2.90%	13.93%	24.52%	46.43%	34.20%	-0.03%
EPS (Basic)	-0.01	-0.01	-0.00	-0.01	-0.00	-0.02
EPS (Diluted)	-0.01	-0.01	-0.00	-0.01	-0.00	-0.02
Free Cash Flow	-3.96	-2.33	-7.56	-6.13	-5.54	-3.8
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01
Gross Margin	43.20%	48.07%	-60.07%	-	-	-
Operating Margin	-594.30%	-530.57%	-360.96%	-	-	-
Profit Margin	-664.85%	-555.78%	-321.37%	-	-	-
Free Cash Flow Margin	-184.87%	-98.12%	-1588.11%	-	-	-
EBITDA	0.01	0.15	-1.72	-5.9	-1.04	-1.45
EBITDA Margin	0.50%	6.17%	-	-	-	-
D&A For EBITDA	12.74	12.74	0	0	0	0
EBIT	-12.73	-12.6	-1.72	-5.91	-1.04	-1.45
Revenue as Reported	-	-	-	-	0.05	0.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.